204 related articles for article (PubMed ID: 35098108)
1. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.
Zolondick AA; Gaudino G; Xue J; Pass HI; Carbone M; Yang H
Precis Cancer Med; 2021 Sep; 4():. PubMed ID: 35098108
[TBL] [Abstract][Full Text] [Related]
2. HMGB1 released by mesothelial cells drives the development of asbestos-induced mesothelioma.
Suarez JS; Novelli F; Goto K; Ehara M; Steele M; Kim JH; Zolondick AA; Xue J; Xu R; Saito M; Pastorino S; Minaai M; Takanishi Y; Emi M; Pagano I; Wakeham A; Berger T; Pass HI; Gaudino G; Mak TW; Carbone M; Yang H
Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2307999120. PubMed ID: 37729199
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos.
Kumagai-Takei N; Yamamoto S; Lee S; Maeda M; Masuzzaki H; Sada N; Yu M; Yoshitome K; Nishimura Y; Otsuki T
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29419731
[TBL] [Abstract][Full Text] [Related]
4. Malignant mesothelioma: facts, myths, and hypotheses.
Carbone M; Ly BH; Dodson RF; Pagano I; Morris PT; Dogan UA; Gazdar AF; Pass HI; Yang H
J Cell Physiol; 2012 Jan; 227(1):44-58. PubMed ID: 21412769
[TBL] [Abstract][Full Text] [Related]
5. Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma.
Testa JR; Kadariya Y; Friedberg JS
Oncoscience; 2024; 11():53-57. PubMed ID: 38784478
[TBL] [Abstract][Full Text] [Related]
6. Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma.
Farahmand P; Gyuraszova K; Rooney C; Raffo-Iraolagoitia XL; Jayasekera G; Hedley A; Johnson E; Chernova T; Malviya G; Hall H; Monteverde T; Blyth K; Duffin R; Carlin LM; Lewis D; Le Quesne J; MacFarlane M; Murphy DJ
Front Toxicol; 2023; 5():1200650. PubMed ID: 37441092
[No Abstract] [Full Text] [Related]
7. Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.
Mirra L; Beretta GL; Lisini D; Marcianti A; Spampinato E; Corno C; Costantino M; Corsico A; Stella GM; Perego P
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38629360
[TBL] [Abstract][Full Text] [Related]
8. Fluoro-edenite induces fibulin-3 overexpression in non-malignant human mesothelial cells.
Rapisarda V; Salemi R; Marconi A; Loreto C; Graziano AC; Cardile V; Basile MS; Candido S; Falzone L; Spandidos DA; Fenga C; Libra M
Oncol Lett; 2016 Nov; 12(5):3363-3367. PubMed ID: 27900005
[TBL] [Abstract][Full Text] [Related]
9. The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.
Fisher SA; Patrick K; Hoang T; Marcq E; Behrouzfar K; Young S; Miller TJ; Robinson BWS; Bueno R; Nowak AK; Lesterhuis WJ; Morahan G; Lake RA
Front Toxicol; 2024; 6():1373003. PubMed ID: 38694815
[No Abstract] [Full Text] [Related]
10. Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.
Napoli F; Listì A; Zambelli V; Witel G; Bironzo P; Papotti M; Volante M; Scagliotti G; Righi L
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073720
[TBL] [Abstract][Full Text] [Related]
11. Role of HMGB1 and its associated signaling pathways in human malignancies.
Idoudi S; Bedhiafi T; Pedersen S; Elahtem M; Alremawi I; Akhtar S; Dermime S; Merhi M; Uddin S
Cell Signal; 2023 Dec; 112():110904. PubMed ID: 37757902
[TBL] [Abstract][Full Text] [Related]
12. Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma.
Fan X; McLaughlin C; Robinson C; Ravasini J; Schelch K; Johnson T; van Zandwijk N; Reid G; George AM
FASEB Bioadv; 2019 Sep; 1(9):550-560. PubMed ID: 32123850
[TBL] [Abstract][Full Text] [Related]
13. The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer.
Cheng YY; Rath EM; Linton A; Yuen ML; Takahashi K; Lee K
Lung Cancer (Auckl); 2020; 11():1-11. PubMed ID: 32021524
[TBL] [Abstract][Full Text] [Related]
14. Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.
Song Y; Baxter SS; Dai L; Sanders C; Burkett S; Baugher RN; Mellott SD; Young TB; Lawhorn HE; Difilippantonio S; Karim B; Kadariya Y; Pinto LA; Testa JR; Shoemaker RH
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804881
[TBL] [Abstract][Full Text] [Related]
15. Mesothelioma: a review.
Mott FE
Ochsner J; 2012; 12(1):70-9. PubMed ID: 22438785
[TBL] [Abstract][Full Text] [Related]
16. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.
Nabavi N; Bennewith KL; Churg A; Wang Y; Collins CC; Mutti L
Genes Cancer; 2016 Nov; 7(11-12):340-354. PubMed ID: 28191281
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.
Tomasetti M; Santarelli L
Cancers (Basel); 2010 Apr; 2(2):523-48. PubMed ID: 24281081
[TBL] [Abstract][Full Text] [Related]
18. How to Better Understand the Influence of Host Genetics on Developing an Effective Immune Response to Thoracic Cancers.
Behrouzfar K; Burton K; Mutsaers SE; Morahan G; Lake RA; Fisher SA
Front Oncol; 2021; 11():679609. PubMed ID: 34235080
[TBL] [Abstract][Full Text] [Related]
19. Updates from the Intestinal Front Line: Autophagic Weapons against Inflammation and Cancer.
Madia F; Grossi V; Peserico A; Simone C
Cells; 2012 Aug; 1(3):535-57. PubMed ID: 24710489
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Cellular Mechanism of Action of Chrysotile Asbestos in MRC5 Cell Line.
Kussainova A; Bulgakova O; Aripova A; Ibragimova M; Pulliero A; Begimbetova D; Bersimbaev R; Izzotti A
J Pers Med; 2023 Nov; 13(11):. PubMed ID: 38003914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
